PROF — Profound Medical Corp.

Summary of Profound Medical (PROF) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $5.3 million for Q3 2025, an 87% increase from $2.8 million in Q3 2024.
  • Recurring Revenue: $4.1 million
  • One-time Capital Equipment Sales: $1.2 million
• Gross Margin: 74.3%, up from 63.1% in Q3 2024.
• Operating Expenses: $12.8 million, compared to $10.8 million in Q3 2024.
• Net Loss: $8 million, or $0.26 per share, improved from a net loss of $9.4 million, or $0.38 per share, in Q3 2024.
• Cash Position: $24.8 million as of September 30, 2025.

2. Strategic Updates and Business Highlights

• Product Launch: Full release of TULSA-AI Volume Reduction software is scheduled for the RSNA meeting, enhancing treatment for benign prostate hyperplasia (BPH).
• Clinical Trials: The CAPTAIN trial has completed recruitment, with data expected to show TULSA's superiority over robotic surgery in various metrics.
• Commercial Momentum: The TULSA-PRO platform is gaining traction, with 70 installed sites and a growing sales pipeline of 93 systems in the final stages of negotiation.
• Partnerships: Strategic partnerships are being established globally, including distribution agreements in Saudi Arabia and Australia.

3. Forward Guidance and Outlook

• Growth Expectations: Management remains confident in achieving 70% to 75% revenue growth for the year, supported by a strong sales pipeline and increasing utilization of TULSA-PRO.
• Profitability Path: The company aims to achieve cash flow positivity as revenue grows and margins remain high, with a focus on limiting shareholder dilution through opportunistic financing.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Despite revenue growth, the company continues to incur significant net losses, raising concerns about long-term sustainability without profitability.
• Reimbursement Uncertainty: While Medicare coverage is improving, the reimbursement landscape remains mixed, with ongoing efforts needed to secure consistent coverage from commercial payers.
• Market Competition: The company faces competitive pressures from other treatment modalities, necessitating continued innovation and effective marketing strategies.

5. Notable Q&A Insights

• Utilization Trends: Management confirmed that the increase in utilization seen in Q3 is continuing into Q4, driven by improved reimbursement pathways.
• Payer Dynamics: Discussions revealed that commercial payers are offering significantly higher reimbursement rates compared to Medicare, enhancing the financial viability of TULSA procedures.
• Sales Pipeline Confidence: The pipeline is described as highly vetted, with expectations that a significant portion will convert into sales, contributing to future revenue growth.
• Sonalleve Technology: There is renewed interest in the Sonalleve platform, with potential applications in treating uterine diseases and cancers, indicating a broader strategic focus beyond prostate treatments.

Overall, Profound Medical is experiencing robust revenue growth and improving margins, while strategically positioning itself for future profitability and market expansion. However, challenges related to ongoing losses and reimbursement complexities remain critical areas to monitor.